EGFR and non-small cell lung carcinoma: Studies in NSCLC showed that 60–80% of the patients with EGFR mutations respond well to erlotinib, but it was evident that patients without these mutations also benefited from erlotinib15, suggesting that EGFR is not a reliable biomarker that could predict for drug response.